Odyssey Health, Inc. (ODYY): M&A transaction — Odyssey Health closes asset sale of brain illness drug candidates to Oragenics for $1M cash and 8M preferred shares

Odyssey Health, Inc.

Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.
Received $1M in cash plus 8M shares of convertible Series F Preferred Stock from Oragenics.
Closing conditions included shareholder approvals from both Odyssey and Oragenics; no material adverse change required.
Odyssey previously disclosed the Purchase Agreement in an October 5, 2023 8-K.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Odyssey Health, Inc. completed a disposition involving Oragenics, Inc. for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (closed 2023-12-28).

Action: disposition
Counterparty: Oragenics, Inc.
Consideration: $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock
Closing: 2023-12-28

Exact text from the filing

to a segment of Odyssey’s business focused on developing medical products that treat brain related illnesses and diseases (the “ Purchased Assets ”) to Oragenics in exchange for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (“ Series F Preferred Stock ”), on and subject to the terms and conditions set forth therein

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Odyssey Health, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-009136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.